Stater Bros. appoints SVP retail operations
SAN BERNARDINO, Calif. — Stater Bros. has promoted its senior regional VP.
The Southern California-based supermarket chain said that Dan Meyer, a 41-year company veteran, has been promoted to the newly created role of SVP retail operations. In this capacity, Meyer will be responsible for the retail operations of all 167 Stater Bros. stores, as well as overseeing the day-to-day operations of the Corporate Training Center. Meyer will report to George Frahm, EVP retail operations and administration.
"Dan is a well-respected and valuable member of our senior management team," Stater Bros. board chairman and CEO Jack Brown said. "This promotion is a result of his leadership skills and the contributions that he has made towards the success of the company’s retail operations department."
Orexigen, FDA work out plan for path to approval of obesity drug
SAN DIEGO — Drug maker Orexigen Therapeutics said it had identified a "clear and feasible path" for the approval of its drug for treating obesity by working with the Food and Drug Administration.
The drug maker said this week that after meeting with officials from the FDA’s Office of New Drugs, it received a list of requirements from the agency about how to design a trial for Contrave (naltrexone and bupropion hydrochloride). The FDA, which declined to approve the drug in January, required that the trial be based on an intent-to-treat analysis, as well as criteria for interpreting the results at interim and final analyses that are similar to those applied to diabetes drugs.
"We have been working with clinical experts, advocacy groups and our partner, Takeda, throughout this process and are pleased with the feedback provided by FDA that identified a very clear and feasible path forward for this important therapy," Orexigen president and CEO Michael Narachi said.
J&J HIV drug shows fewer side effects in trial data analysis
CHICAGO — A new study has found that a recently approved drug for HIV produces fewer unpleasant side effects during the first three months of therapy than the standard treatment, according to published reports.
MedPage Today reported that a study presented at the Interscience Conference on Anti-Microbial Agents and Chemotherapy found that Johnson & Johnson’s Edurant (rilpivirine) was easier to take than Bristol-Myers Squibb’s Sustiva (efavirenz).
The study found that use of Edurant resulted in fewer of the neurological side effects that patients experience when taking Sustiva, such as dizziness and abnormal dreams or nightmares, as well as rashes. The study was an analysis of data from the "ECHO" and "THRIVE" clinical trials, which enrolled a total of 1,368 patients.